EnBiotix Revitalize Existing Antibiotics To Fight Drug-Resistant Bacterial Infections

EnBiotix Revitalize Existing Antibiotics To Fight Drug-Resistant Bacterial Infections
Drug-resistant bacteria threatens the effective prevention and treatment of an ever-increasing range of infections. Drug-resistance is present in all parts of the world and is a serious threat to global public health. In USA alone at least 2 million people become infected with bacteria that are resistant to first-line antibiotic treatments, costing the health system 20 billion USD annually. Today, more than 700 000 people die each year from drug-resistant bacterial infections, and unless action is taken, a report estimate that this number could balloon to 10 million each year by 2050, and cost a staggering 100 trillion USD.
 
The startup EnBiotix is determined to combat the global rise of drug-resistant bacterial infections. By combining synthetic and systems biology technologies developed by Prof. James J. Collins at MIT, they enable the development of both novel antibiotics and potentiators of existing antibiotics to transform and revitalize their spectrum of activity. The startups unique product pipeline target a wide range of acute and chronic infections, addressing a significant and growing need globally.
 
Currently, EnBiotix’s pipeline consists of three products; EBX-001, EBX-002 and EPP-001. EBX-001 combines tobramycin with a potentiator as a novel, inhaled investigational treatment for P. aeruginosa infections in cystic fibrosis (CF), non-CF bronchiectasis and COPD patients. With millions of patients potentially eligible for EBX-001 treatment worldwide, it not only has a multibillion dollar market potential, but a unique potential to reduce morbidity, mortality and treatment burden to both patients and their families. EBX-002 is also a potentiator that is administered in combination with a proprietary aminoglycoside for gram-negative catheter-associated urinary tract infections in hospital settings, affecting over 1 million globally and a market potential of nearly $1 billion. And lastly, EPP-001 is an engineered bacteriophage which will be developed in combination with standard antibiotic therapy for the treatment of prosthetic joint infections, a debilitating infection that is expected to grow dramatically with an aging population.
 
The startup is not afraid to take on the growing crisis of drug-resistant bacterial infections, a $40 billion market that has been attributed to the misuse of antibiotics, as well as a lack of new drug development by the pharmaceutical industry. EnBiotix could significantly reduce the costs associated with drug-resistant bacterial infection, estimated to be trillions of dollars by 2050. Most importantly, their pipeline address a wide range of infections, each with a huge potential of giving the lives back to millions of people globally who each day fight against these hard-to-treat infections.
 
In May 2016, EnBiotix announced the completion of a Series A financing, with investors including Wired Holdings Investment Corp. (WHICH), and Apeiron Holdings Limited (AHL). WHICH and EnBiotix will establish a new joint venture company in Brazil, with the purpose of developing and commercializing EnBiotix’s product portfolio throughout Latin America. The Latin American pharmaceutical market currently generates approximately $90 billion in revenues and is growing between 10 to 15 percent annually, and they aim to grow EnBiotix into a key market leader in this region.
If you appreciate our work, consider making a contribution